bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Neoplasms
Genetics
 Resources from HONselect
Gene May Boost Death Risk From Most Common Thyroid Cancer
But survival rates for papillary thyroid cancer are still high, experts note

By Robert Preidt

FRIDAY, April 12 (HealthDay News) -- Researchers have pinpointed a genetic mutation that is strongly associated with an increased risk of death in people with thyroid cancer.

The investigators followed more than 1,800 patients after their initial treatment for papillary thyroid cancer, which accounts for 85 percent to 90 percent of all thyroid cancers.

After an average follow-up period of 33 months, 5 percent of those with the BRAF V600E mutation had died, compared with 1 percent of those without the mutation, according to the study in the April 10 issue of the Journal of the American Medical Association.

However, the link between this mutation and increased risk of death was not independent of tumor characteristics, the study authors noted in a journal news release.

This, and the fact that the overall death rate from papillary thyroid cancer is low, means that it is unclear how to use these findings to reduce death risk in patients with this type of cancer, said Dr. Mingzhao Xing, of the Johns Hopkins University School of Medicine, and colleagues.

The overall five-year survival rate for patients with papillary thyroid cancer is 95 percent to 97 percent. It's a challenge to distinguish patients who require aggressive treatment in order to reduce their risk of death from patients who do not, the researchers explained.

Even so, the authors of an accompanying editorial pointed out that the study provided important insight.

According to the editorialists, Dr. Anne Cappola and Dr. Susan Mandel of the University of Pennsylvania, "Although these findings do not support widespread BRAF V600E testing, they do support the need for additional study of how BRAF testing can be used to improve the already excellent prognosis of patients with papillary thyroid cancer."

While the study found an association between the gene mutation and thyroid cancer survival, it did not establish a cause-and-effect relationship.

More information

The American Cancer Society has more about thyroid cancer.

SOURCE: Journal of the American Medical Association, news release, April 9, 2013

Health News Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=675179

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Thyroid Gland
Thyroid Neoplasms
Death
Risk
Association
Research Personnel
Therapeutics
Survival Rate
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact